Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Accelereret bilateral rTMS på geriatrisk depression

15. november 2026 opdateret af: National Taiwan University Hospital

Terapeutisk effekt af accelereret bilateral gentagen transkraniel magnetisk stimulering på geriatrisk depression: et prospektivt dobbeltblindt, randomiseret kontrolleret forsøg

This study aims to evaluate the efficacy of accelerated bilateral repetitive transcranial magnetic stimulation (rTMS) on major depression, anxiety, cognitive function and physiological parameters in elderly depressive patients.

Studieoversigt

Detaljeret beskrivelse

Repeated transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation treatment, showing good therapeutic effect to medicine treatment-refractory patients. Recent studies suggested bilateral DLPFC might be effective to geriatric depression. Accelerated treatment course was reported to have similar therapeutic effect and safety profile with traditional course. The investigators hypothesize accelerated bilateral rTMS is effective to geriatric depression and comorbid anxiety.

Cognitive impairment and decreased parasympathetic tone are common in patients with major depression. The investigators hypothesize cognitive function and physiological indicators improve after accelerated bilateral rTMS.

In this single-center, prospective double-blind, randomized, active-controlled trial, the investigators aim to recruit 100 patients older than 60 years, without neurocognitive disorders, and refractory to one or more antidepressants. The experimental group would receive an rTMS course with high-frequency stimulation at left DLPFC followed by low-frequency inhibition at right DLPFC, two sessions daily, five days a week, and two weeks in total. The standard treatment group would receive an rTMS course with high-frequency stimulation at left DLPFC as standard treatment parameters. Mood, cognition and physiological markers would be monitored every week. The primary outcome is response and remission rate of major depression measured by Hamilton Rating Scale for Depression.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

2

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Douliu, Taiwan
        • Department of Psychiatry, National Taiwan University Hospital, Yun-Lin Branch

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

60 år til 85 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • age between 60-85 years
  • literate and received basic education for at least 2 years
  • diagnosis of major depressive disorder, without psychotic features, according to DSM-5
  • have a score of 20 or greater on the 17-item Hamilton Depression Rating Scale
  • failed to achieve clinical response by at least 1 antidepressant trial of sufficient dosage for at least 4 weeks
  • psychoactive agents were in stable doses before randomization

Exclusion Criteria:

  • active suicide plans or attempts; or suicide attempts in the last 12 months
  • diagnosis of schizophrenia or bipolar disorder according to DSM-5
  • have DSM-5-confirmed substance use disorder (excluding tobacco) in the last 3 months
  • have delirium, major neurocognitive disorder or MMSE < 24
  • current use of bupropion >300 mg/day, tricyclic antidepressant, clozapine, chlorpromazine, foscarnet, ganciclovir, ritonavir, theophylline or anti-epileptic agents excluding benzodiazepines
  • history of severe head trauma, epilepsy, multiple sclerosis, stroke, brain tumors, intracranial aneurysm, active intracranial infection, increased intracranial pressure, metallic implants in the brain, major brain surgery or major neurological diseases
  • with a cardiac pacemaker or defibrillator
  • received rTMS treatment before

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Experimental Group

The experimental group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by low-frequency (1Hz) inhibition at right DLPFC (120% motor threshold, 10 trains, 1200 pulses), two sessions daily with a 1.5-hour inter-session interval (L't active-R't active-1.5 hr-L't active-R't active), five days a week, and two weeks in total.

Magstim® Super Rapid² Transcranial Magnetic Stimulation System

Aktiv komparator: Standard Treatment Group

The standard treatment group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by sham inhibition at right DLPFC (1Hz, 10 trains, 1200 pulses); after a 1.5-hour inter-session interval, a sham session would be administered at left and right DLPFC (L't active-R't sham-1.5 hr-L't sham-R't sham. The course would be applied five days a week, and two weeks in total.

Magstim® Super Rapid² Transcranial Magnetic Stimulation System

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Degree of Change in 17-item Hamilton Depression Rating Scale (HAM-D 17)
Tidsramme: day 1, day 5, day 12, day 19

HAM-D 17 is a scale rating the severity of depression, covering emotional, cognitive and somatic symptoms of depression. Higher scores indicate higher severity. Response to treatment is defined as ≥ 50% decrease in HAM-D 17; remission is defined as ≤ 7 points in HAM-D 17.

day 1, day 5, day 12, day 19

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Degree of Change in Hamilton Anxiety Rating Scale (HAM-A)
Tidsramme: day 1, day 5, day 12, day 19

HAM-A is a scale rating the severity of anxiety, covering emotional, cognitive and somatic symptoms of anxiety. Higher scores indicate higher severity.

day 1, day 5, day 12, day 19
Degree of Change in Mini-Mental State Examination (MMSE)
Tidsramme: day 1, day 5, day 12, day 19

MMSE is a wildly-used tool to evaluate several cognitive function domains.

day 1, day 5, day 12, day 19
Degree of Change in Stroop Test
Tidsramme: day 1, day 5, day 12, day 19

Task 1 (word phase) requests a subject to say a color name string (red, green, blue) printed in black; Task 2 (color phase) requests a subject to say the printed colors (red, green, blue) of letter "x" string; Task 3 (interference phase) requests a subject to say the printed colors of a string of color names (red, green, blue).

day 1, day 5, day 12, day 19
Degree of Change in Trail Making Test
Tidsramme: day 1, day 5, day 12, day 19

Task 1 requests a subject to connect a sequence of 25 consecutive numbers regardless of their colors; Task 2 requires a subject to connect 25 consecutive numbers in alternative colors.

day 1, day 5, day 12, day 19
Degree of Change in Verbal Fluency Test
Tidsramme: day 1, day 5, day 12, day 19

This test requests a subject to speak as many names of vegetables, fishes or fruit as possible in 45 seconds.

day 1, day 5, day 12, day 19
Degree of Change in Physiological Parameters
Tidsramme: day 1, day 5, day 12, day 19

ProComp5 Infiniti (SA7525) Biofeedback System would be used. Heart rate variability, skin conductance, body temperature and respiratory rate would be measured.

day 1, day 5, day 12, day 19

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

23. november 2020

Primær færdiggørelse (Faktiske)

21. december 2022

Studieafslutning (Faktiske)

21. december 2022

Datoer for studieregistrering

Først indsendt

15. juli 2020

Først indsendt, der opfyldte QC-kriterier

22. juli 2020

Først opslået (Faktiske)

24. juli 2020

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

15. november 2026

Sidst verificeret

1. maj 2021

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner